BofA/Merrill Lynch Upgrades Optimer Pharma (OPTR) to Buy
Tweet
Share
E-mailGet Alerts OPTR Hot Sheet
Price: $12.78 --0%
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
3 Buy, 8 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Shares of Optimer Pharmaceuticals (NASDAQ: OPTR) are indicated nearly 4 percent higher in pre-market action Monday following an upgrade from an analyst at BofA Merrill earlier.
The stock is now rated a Buy, up from a prior Neutral rating.
Optimer shares last traded at $13.64.
For more ratings news on Optimer Pharmaceuticals click here and for the rating history of Optimer Pharmaceuticals click here.
The stock is now rated a Buy, up from a prior Neutral rating.
Optimer shares last traded at $13.64.
For more ratings news on Optimer Pharmaceuticals click here and for the rating history of Optimer Pharmaceuticals click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- BofA Securities Starts Kanzhun Ltd. (BZ) at Neutral
- JPMorgan Upgrades Hyundai Marine and Fire Insurance (001450:KS) to Neutral
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
